1. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004;10(2):307-12.
2. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3(4):692-4.
3. Liu GJ, Wang YF, Chen PY, et al. The efficacy and safety of novel oral anticoagulants for the preventive treatment in Atrial fibrillation patients: a systematic review and meta-analysis. Drug Deliv 2014;21(6):436-52.
4. Nileshkumar J Patel, Varunsiri Atti, Raul D Mitrani,Juan F Viles-Gonzalez, Jeffrey J Goldberger. Global rising trends of Atrial fibrillation:a major public health concern. Heart 2018;(0):1–2
5. Darby-Stewart A, Dachs R, Graber MA. Rivaroxaban vs. warfarin for stroke prevention in patients with nonvalvular Atrial fibrillation. Am Fam Physician 2012;85(6):577-86.
6. Chugh, Sumeet S et al. Worldwide epidemiology of Atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation2014;129(8): 837-47.
7. Xue Li, Vicki C. Tse, Lung Wai Au-Doung, Ian C.K. Wong, Esther W. Chan. The impact of ischaemic stroke on Atrial fibrillation-related healthcare cost: a systematic review. EP Europace 2017;19(6):937–947
8. Deirdre A. Lane, Flemming Skjøth, Gregory Y. H. Lip, Torben B. Larsen, Dipak Kotecha. Temporal Trends in Incidence, Prevalence, and Mortality of Atrial fibrillation in Primary Care. Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease 2017;6(5):e005155
9. Hansen PW, Sehested TSG, Fosbol EL, et al. Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with Atrial fibrillation between 1996 and 2011. PLoS One 2018;13(3):e0194295.
10. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for Atrial fibrillation: population-based estimates. Am J Cardiol 1998;82(8A):2N-9N.
11. Sérgio Barra, Simon Fynn. Untreated Atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. Journal of the Saudi Heart Association 2015;27(1): 31-43
12. Kara E. Montbleau, Deandre King, Lori Henault, Jared W Magnani & Albert Lee (Reviewing Editor). Health literacy, health-related quality of life, and Atrial fibrillation. Cogent Medicine 2017; 4(1)
13. Graham Thrall, Deirdre Lane, Douglas Carroll, Gregory Y.H. Lip. Quality of Life in Patients with Atrial fibrillation: A Systematic Review. The American Journal of Medicine 2006; 119(5) 448.e1-448.e19
14. Spertus, J., et al. Development and Validation of the Atrial fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial fibrillation. Circulation: Arrhythmia and Electrophysiology 2011;4(1): 15-25.
15. Hagens VE et al. Effect of rate or rhythm control on quality of life in persistent Atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241-7.
16. National Clinical Guideline Centre. Atrial fibrillation: the management of Atrial fibrillation. Clinical guideline: Methods, evidence and recommendations. June 2014.
17. Anderson, J. L., et al. Management of Patients With Atrial fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations). Circulation 2013 127(18): 1916-1926.
18. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with Atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:2246–2280.
19. Xu J, Luc JG, Phan K. Atrial fibrillation: review of current treatment strategies. J Thorac Dis. 2016;8(9):E886–E900.
20. Wallis CJD, Juvet T, Lee Y, et al. Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA 2017;318(13):1260-71.
21. Gorman EW, Perkel D, Dennis D, Yates J, Heidel RE, Wortham D. Validation Of The HAS-BLED Tool In Atrial fibrillation Patients Receiving Rivaroxaban. J Atr Fibrillation 2016;9(2):1461.
22. Dar T, Yarlagadda B, Vacek J, et al. Management of Stroke risk in Atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more. J Atr Fibrillation 2017;10(4):1729.
23. Gerhard Hindricks et al. ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of Atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of Atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, European Heart Journal, 2021;42(5): 373–498.
24. Res LCS, Lubberts B, Shah SH, et al. Health-related quality of life after adverse bleeding events associated with antithrombotic drug therapy - A systematic review. Hellenic J Cardiol 2019;60(1):3-10.
25. Herdman, M., Gudex, C., Lloyd, A. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727–1736.
26. Ware, J. E., Jr. (1999). SF-36 Health Survey. In M. E. Maruish (Ed.), The use of psychological testing for treatment planning and outcomes assessment:1227-1246
27. Badia, X., Arribas, F., Ormaetxe, J.M. et al. Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with Atrial fibrillation (AF-QoL). Health Qual Life Outcomes 2007 5(37)
28. Xiao-Jun Lin, I-Mei Lin, Sheng-Yu Fan. Methodological issues in measuring health-related quality of life. Tzu Chi Medical Journal 2013;25(1):8-12,
29. Bae JM. Value-based medicine: concepts and application. Epidemiol Health. 2015;37:e2015014.
30. Riva S and Pravettoni G. Value-Based Model: A New Perspective in Medical Decision-making. Front. Public Health 2016 4:118
31. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–47.
32. Rodeghiero, F.; Tosetto, A.; Abshire, T.; Arnold, DM.; Coller, B.; James, P.; Neunert, C.; Lillicrap, D. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010;8 (9): 2063–5
33. Virginia Braun & Victoria Clark. Using thematic analysis in psychology, Qualitative Research in Psychology, 2006 3(2): 77-101
34. Buchholz, I., Janssen, M.F., Kohlmann, T. et al. A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D. PharmacoEconomics 2018 36, 645–661
35. De Caterina R, Brüggenjürgen B, Darius H, et al. Quality of life and patient satisfaction in patients with Atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. Arch Cardiovasc Dis. 2018;111(2):74-84.
36. Porter ME, Lee TH. The Strategy that will fix healthcare. Harvard Business Review October 2013
37. Public Health England. Atrial fibrillation prevalence estimates for local populations. Estimates of the number of people with Atrial fibrillation in GP practices and clinical commissioning group (CCG) areas in England. April 2020 Available at: https://www.gov.uk/government/publications/atrial-fibrillation-prevalence-estimates-for-local-populations
38. Hill NR, Ayoubkhani D, McEwan P,Sugrue DM, Farooqui U, Lister S, et al. (2019) Predicting Atrial fibrillation in primary care using machine learning. PLoS ONE 14(11): e0224582
39. Michael Levine, Joshua N. Goldstein; Bleeding complications of targeted oral anticoagulants: what is the risk?. Hematology Am Soc Hematol Educ Program 2014; 2014 (1): 504–509